vs
杜比实验室（DLB）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是杜比实验室的2.0倍（$772.1M vs $395.6M），杜比实验室净利率更高（24.0% vs 12.7%，领先11.3%），杜比实验室同比增速更快（7.1% vs 5.9%），过去两年杜比实验室的营收复合增速更高（13.9% vs 9.0%）
杜比实验室是一家美国科技企业，专注于音频降噪、音频编码压缩、空间音频及高动态范围（HDR）影像等技术的研发，旗下技术广泛授权给全球各地的消费电子制造商使用，助力终端产品为用户带来更出色的视听体验。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
DLB vs RVTY — 直观对比
营收规模更大
RVTY
是对方的2.0倍
$395.6M
营收增速更快
DLB
高出1.2%
5.9%
净利率更高
DLB
高出11.3%
12.7%
两年增速更快
DLB
近两年复合增速
9.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $395.6M | $772.1M |
| 净利润 | $94.9M | $98.4M |
| 毛利率 | 88.7% | — |
| 营业利润率 | 28.5% | 14.5% |
| 净利率 | 24.0% | 12.7% |
| 营收同比 | 7.1% | 5.9% |
| 净利润同比 | 3.4% | 3.9% |
| 每股收益（稀释后） | $0.99 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DLBRVTY
| Q2 26 | $395.6M | — | ||
| Q1 26 | $346.7M | — | ||
| Q4 25 | $346.7M | $772.1M | ||
| Q3 25 | $307.0M | $698.9M | ||
| Q2 25 | $315.5M | $720.3M | ||
| Q1 25 | $369.6M | $664.8M | ||
| Q4 24 | $357.0M | $729.4M | ||
| Q3 24 | $304.8M | $684.0M |
净利润DLBRVTY
| Q2 26 | $94.9M | — | ||
| Q1 26 | $53.3M | — | ||
| Q4 25 | $53.3M | $98.4M | ||
| Q3 25 | $49.3M | $46.7M | ||
| Q2 25 | $46.1M | $53.9M | ||
| Q1 25 | $91.8M | $42.2M | ||
| Q4 24 | $67.8M | $94.6M | ||
| Q3 24 | $58.6M | $94.4M |
毛利率DLBRVTY
| Q2 26 | 88.7% | — | ||
| Q1 26 | 87.5% | — | ||
| Q4 25 | 87.5% | — | ||
| Q3 25 | 87.1% | 53.6% | ||
| Q2 25 | 86.1% | 54.5% | ||
| Q1 25 | 90.3% | 56.5% | ||
| Q4 24 | 88.6% | — | ||
| Q3 24 | 88.8% | 56.3% |
营业利润率DLBRVTY
| Q2 26 | 28.5% | — | ||
| Q1 26 | 17.9% | — | ||
| Q4 25 | 17.9% | 14.5% | ||
| Q3 25 | 9.7% | 11.7% | ||
| Q2 25 | 15.1% | 12.6% | ||
| Q1 25 | 29.2% | 10.9% | ||
| Q4 24 | 22.4% | 16.3% | ||
| Q3 24 | 15.2% | 14.3% |
净利率DLBRVTY
| Q2 26 | 24.0% | — | ||
| Q1 26 | 15.4% | — | ||
| Q4 25 | 15.4% | 12.7% | ||
| Q3 25 | 16.1% | 6.7% | ||
| Q2 25 | 14.6% | 7.5% | ||
| Q1 25 | 24.8% | 6.4% | ||
| Q4 24 | 19.0% | 13.0% | ||
| Q3 24 | 19.2% | 13.8% |
每股收益（稀释后）DLBRVTY
| Q2 26 | $0.99 | — | ||
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.55 | $0.86 | ||
| Q3 25 | $0.50 | $0.40 | ||
| Q2 25 | $0.48 | $0.46 | ||
| Q1 25 | $0.94 | $0.35 | ||
| Q4 24 | $0.70 | $0.77 | ||
| Q3 24 | $0.59 | $0.77 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $594.7M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.6B | $7.3B |
| 总资产 | $3.2B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DLBRVTY
| Q2 26 | $594.7M | — | ||
| Q1 26 | $644.6M | — | ||
| Q4 25 | $644.6M | $919.9M | ||
| Q3 25 | $702.6M | $931.4M | ||
| Q2 25 | $699.3M | $991.8M | ||
| Q1 25 | $626.6M | $1.1B | ||
| Q4 24 | $520.8M | $1.2B | ||
| Q3 24 | $482.0M | $1.2B |
股东权益DLBRVTY
| Q2 26 | $2.6B | — | ||
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.6B | $7.3B | ||
| Q3 25 | $2.6B | $7.4B | ||
| Q2 25 | $2.6B | $7.6B | ||
| Q1 25 | $2.6B | $7.6B | ||
| Q4 24 | $2.5B | $7.7B | ||
| Q3 24 | $2.5B | $7.9B |
总资产DLBRVTY
| Q2 26 | $3.2B | — | ||
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $12.2B | ||
| Q3 25 | $3.2B | $12.1B | ||
| Q2 25 | $3.2B | $12.4B | ||
| Q1 25 | $3.2B | $12.4B | ||
| Q4 24 | $3.2B | $12.4B | ||
| Q3 24 | $3.1B | $12.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $147.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 1.55× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流DLBRVTY
| Q2 26 | $147.3M | — | ||
| Q1 26 | $54.8M | — | ||
| Q4 25 | $54.8M | $182.0M | ||
| Q3 25 | $472.2M | $138.5M | ||
| Q2 25 | $67.7M | $134.3M | ||
| Q1 25 | $174.9M | $128.2M | ||
| Q4 24 | $106.8M | $174.2M | ||
| Q3 24 | $327.3M | $147.9M |
自由现金流DLBRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | $161.8M | ||
| Q3 25 | $435.9M | $120.0M | ||
| Q2 25 | $61.3M | $115.5M | ||
| Q1 25 | $168.0M | $112.2M | ||
| Q4 24 | $100.0M | $149.8M | ||
| Q3 24 | $297.2M | $125.6M |
自由现金流率DLBRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 14.5% | 21.0% | ||
| Q3 25 | 142.0% | 17.2% | ||
| Q2 25 | 19.4% | 16.0% | ||
| Q1 25 | 45.5% | 16.9% | ||
| Q4 24 | 28.0% | 20.5% | ||
| Q3 24 | 97.5% | 18.4% |
资本支出强度DLBRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.3% | 2.6% | ||
| Q3 25 | 11.8% | 2.6% | ||
| Q2 25 | 2.0% | 2.6% | ||
| Q1 25 | 1.9% | 2.4% | ||
| Q4 24 | 1.9% | 3.4% | ||
| Q3 24 | 9.8% | 3.3% |
现金转化率DLBRVTY
| Q2 26 | 1.55× | — | ||
| Q1 26 | 1.03× | — | ||
| Q4 25 | 1.03× | 1.85× | ||
| Q3 25 | 9.57× | 2.97× | ||
| Q2 25 | 1.47× | 2.49× | ||
| Q1 25 | 1.91× | 3.03× | ||
| Q4 24 | 1.57× | 1.84× | ||
| Q3 24 | 5.59× | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DLB
| Licensing | $372.2M | 94% |
| Products and services | $23.4M | 6% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
